Skip to Content

Drug Interactions between Movantik and Relistor

This report displays the potential drug interactions for the following 2 drugs:

  • Movantik (naloxegol)
  • Relistor (methylnaltrexone)

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

methylnaltrexone naloxegol

Applies to: Relistor (methylnaltrexone) and Movantik (naloxegol)

Using methylnaltrexone together with naloxegol may increase the risk of opioid withdrawal symptoms such as sweating, tearing, runny nose, chills, diarrhea, abdominal pain, anxiety, insomnia, irritability, restlessness, and yawning. These medications should generally not be used together. Talk to your doctor if you have any questions or concerns. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Switch to professional interaction data

Drug and food interactions

Major

naloxegol food

Applies to: Movantik (naloxegol)

Do not consume grapefruit or grapefruit juice during treatment with naloxegol. Grapefruit juice can significantly increase the blood levels of naloxegol. You may be more likely to experience side effects and withdrawal symptoms such as sweating, tearing, runny nose, chills, diarrhea, abdominal pain, anxiety, insomnia, irritability, restlessness, and yawning. Taking naloxegol with food can also increase its absorption into the blood stream. Therefore, you should take it on an empty stomach at least 1 hour before or 2 hours after a meal. Talk to your doctor or pharmacist if you have questions on how to take this or other medications you are prescribed. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Switch to professional interaction data

Moderate

methylnaltrexone food

Applies to: Relistor (methylnaltrexone)

Food may reduce the absorption of methylnaltrexone when taken orally, which may lead to lower blood levels of the medication and possibly reduced effectiveness. You should take oral preparations of methylnaltrexone on an empty stomach at least 30 minutes before your first meal of the day.

Switch to professional interaction data

Therapeutic duplication warnings

Therapeutic duplication is the use of more than one medicine from the same drug category or therapeutic class to treat the same condition. This can be intentional in cases where drugs with similar actions are used together for demonstrated therapeutic benefit. It can also be unintentional in cases where a patient has been treated by more than one doctor, or had prescriptions filled at more than one pharmacy, and can have potentially adverse consequences.

Duplication

Peripheral opioid receptor antagonists

Therapeutic duplication

The recommended maximum number of medicines in the 'peripheral opioid receptor antagonists' category to be taken concurrently is usually one. Your list includes two medicines belonging to the 'peripheral opioid receptor antagonists' category:

  • Movantik (naloxegol)
  • Relistor (methylnaltrexone)

Note: The benefits of taking this combination of medicines may outweigh any risks associated with therapeutic duplication. This information does not take the place of talking to your doctor. Always check with your healthcare provider to determine if any adjustments to your medications are needed.

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide